expand vertex collabor includ dmd
crispr vertex expand allianc develop gene edit medicin treat
duchenn muscular dystrophi dmd myoton dystrophi type crispr
receiv million cash up-front elig billion mileston plu tier
royalti vertex develop commerci dmd compani share
cost crispr retain option co-develop/co-commerci time
ind file crispr vertex alreadi partner current
phase i/ii studi transfusion-depend beta thalassemia sickl cell diseas
data like crispr also advanc wholly-own pipelin allogen gene
edit car-t estim crispr hold pro forma cash million crispr
remain top pick reiter overweight rate increas
price target
expand vertex allianc crispr vertex expand allianc develop
gene edit medicin treat dmd crispr receiv million
cash up-front elig billion mileston plu tier royalti vertex
develop commerci dmd compani share cost
crispr retain option co-develop/co-commerci time ind file
data crispr vertex alreadi partner
believ crispr ex vivo approach biolog rational target fetal hemoglobin
hbf de-risk differenti gene edit program crispr
treat first transfusion-depend beta-th patient germani crispr state
enrol on-go suggest first beta-th patient success
graft first scd patient enrol may treat
continu believ first-in-man data later year
serv import valu driver crispr gene edit field
first car-t studi start soon ind cta car-t
approv crispr expect initi phase i/ii studi soon
target bcma target follow crispr present
new target car-t aml
technolog unproven may fail man crispr involv
patent litig could advers effect compani abil conduct busi
compani like requir futur capit
crsp pioneer develop therapeut genom edit
price close june
proj ev net cash
april
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
reiter overweight rate increas price target ad
valu vertex deal roll forward discount period price target
base increas project enterpris valu billion billion
valu beta-thalassemia billion appli standard multipl
ebitda billion discount back prior valu
beta-thalassemia billion appli multipl ebitda
million discount back valu sickl cell
diseas billion appli multipl ebitda billion discount
prior valu sickl cell diseas billion
appli multipl ebitda million discount
multipl standard higher margin ebitda profit share view discount rate
appropri phase i/ii asset potenti acceler approv
valu wholli own million million appli
standard multipl sale million discount back
continu valu wholli own bcma allogen
car-t million
today ad million vertex partner dmd also add
million viacyt partner type diabet program continu valu crispr portion
casebia joint ventur million
factor million vertex up-front payment dmd add project
cash million cash million divid increas
billion market cap million share arriv increas price target
pleas see exhibit
page
page
thousand except per share
research develop
gener administr
compani report piper jaffray estim
current disclosur inform compani found
